BACKGROUND: Circulating blasts (peripheral blood [PB] blasts) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts have incremental value with regard to patient prognostication is unclear. Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts. METHODS: The authors retrospectively studied 1316 patients with myelofibrosis who presented at their institution between 1984 and 2018 and had available PB and BM blasts. RESULTS: The PB blast percentage influenced overall survival (OS) only among patients who had BM blasts <5%, with a median OS of 64 months for patients with 0% PB blasts, 48 months for those with 1% to 3% PB blasts, and 22 months for those with 4% PB blasts (P < .01). Patients who had 4% PB blasts and 5% to 9% BM/PB blasts had clinical features similar to those of patients who had 10% to 19% blasts. Although the OS of the former patients was longer than in patients who had 10% to 19% blasts, it was not statistically different (median OS: 22, 26, and 13 months, respectively; P > .05). Forty-four percent of patients received RUX throughout their disease course. All patients who had <10% blasts (PB or BM) and received treatment with RUX had superior OS compared with those who did not receive RUX within the same group. PB blasts ≥4% and BM blasts ≥5% were significant for predicting inferior survival in multivariate analysis. CONCLUSIONS: The current results provide comprehensive insight into the role of peripheral blasts in patients with myelofibrosis and indicates that patients who have PB blasts ≥4% have an unfavorable prognosis. RUX provides a survival benefit to patients who have PB blasts <10%.
BACKGROUND: Circulating blasts (peripheral blood [PB] blasts) ≥1% have long been considered an unfavorable feature for patients with primary myelofibrosis. Whether further quantification of PB blasts and their correlation with bone marrow (BM) blasts have incremental value with regard to patient prognostication is unclear. Similarly, the role of the JAK1/JAK2 inhibitor ruxolitinib (RUX) is not well defined in patients who have increased blasts. METHODS: The authors retrospectively studied 1316 patients with myelofibrosis who presented at their institution between 1984 and 2018 and had available PB and BM blasts. RESULTS: The PB blast percentage influenced overall survival (OS) only among patients who had BM blasts <5%, with a median OS of 64 months for patients with 0% PB blasts, 48 months for those with 1% to 3% PB blasts, and 22 months for those with 4% PB blasts (P < .01). Patients who had 4% PB blasts and 5% to 9% BM/PB blasts had clinical features similar to those of patients who had 10% to 19% blasts. Although the OS of the former patients was longer than in patients who had 10% to 19% blasts, it was not statistically different (median OS: 22, 26, and 13 months, respectively; P > .05). Forty-four percent of patients received RUX throughout their disease course. All patients who had <10% blasts (PB or BM) and received treatment with RUX had superior OS compared with those who did not receive RUX within the same group. PB blasts ≥4% and BM blasts ≥5% were significant for predicting inferior survival in multivariate analysis. CONCLUSIONS: The current results provide comprehensive insight into the role of peripheral blasts in patients with myelofibrosis and indicates that patients who have PB blasts ≥4% have an unfavorable prognosis. RUX provides a survival benefit to patients who have PB blasts <10%.
Authors: Rajyalakshmi Luthra; Keyur P Patel; Neelima G Reddy; Varan Haghshenas; Mark J Routbort; Michael A Harmon; Bedia A Barkoh; Rashmi Kanagal-Shamanna; Farhad Ravandi; Jorge E Cortes; Hagop M Kantarjian; L Jeffrey Medeiros; Rajesh R Singh Journal: Haematologica Date: 2013-10-18 Impact factor: 9.941
Authors: Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi Journal: Leukemia Date: 2007-08-30 Impact factor: 11.528
Authors: Claire N Harrison; Nicolaas Schaap; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Ramon V Tiu; Pierre Zachee; Eric Jourdan; Elliott Winton; Richard T Silver; Harry C Schouten; Francesco Passamonti; Sonja Zweegman; Moshe Talpaz; Joanne Lager; Zhenming Shun; Ruben A Mesa Journal: Lancet Haematol Date: 2017-06-08 Impact factor: 18.959
Authors: John T Reilly; Mary Frances McMullin; Philip A Beer; Nauman Butt; Eibhlean Conneally; Andrew Duncombe; Anthony R Green; N George Michaeel; Marie H Gilleece; Georgina W Hall; Steven Knapper; Adam Mead; Ruben A Mesa; Mallika Sekhar; Bridget Wilkins; Claire N Harrison Journal: Br J Haematol Date: 2012-06-01 Impact factor: 6.998
Authors: Rangit R Vallapureddy; Mythri Mudireddy; Domenico Penna; Terra L Lasho; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Kebede H Begna; Naseema Gangat; Animesh Pardanani; Ayalew Tefferi Journal: Blood Cancer J Date: 2019-01-25 Impact factor: 11.037
Authors: John O Mascarenhas; Raajit K Rampal; Heidi E Kosiorek; Rupali Bhave; Elizabeth Hexner; Eunice S Wang; Aaron Gerds; Camille N Abboud; Marina Kremyanskaya; Dimitry Berenzon; Olatoyosi Odenike; Noushin Farnoud; Aishwarya Krishnan; Rona Singer Weinberg; Erin McGovern; Mohamed E Salama; Vesna Najfeld; Juan S Medina-Martinez; Juan E Arango Ossa; Max F Levine; Yangyu Zhou; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Ronald Hoffman Journal: Blood Adv Date: 2020-10-27
Authors: Nico Gagelmann; Christine Wolschke; Rachel B Salit; Thomas Schroeder; Markus Ditschkowski; Victoria Panagiota; Bruno Cassinat; Felicitas Thol; Anita Badbaran; Marie Robin; Hans Christian Reinhardt; Francis Ayuk; Michael Heuser; Bart L Scott; Nicolaus Kröger Journal: Blood Adv Date: 2022-02-22